Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | Developments in the treatment of myeloma

Mahmoud Gaballa • 5 Feb 2021
TCT 2021
Multiple Myeloma Daratumumab

Mahmoud Gaballa, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explores future developments in the treatment and management of patients with multiple myeloma, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Mahmoud Gaballa

Selecting patients with multiple myeloma for CAR-T therapy
0:48
Selecting patients with multiple myeloma for CAR-T therapy
Mahmoud Gaballa • 2 Jun 2024
BCMA-targeted CAR-T therapy is tolerable in multiple myeloma with CNS involvement
1:27
BCMA-targeted CAR-T therapy is tolerable in multiple myeloma with CNS involvement
Mahmoud Gaballa • 2 Jun 2024
Latest advances in CAR-T for multiple myeloma: cilta-cel & new CAR-T platforms
2:35
Latest advances in CAR-T for multiple myeloma: cilta-cel & new CAR-T platforms
Mahmoud Gaballa • 22 Apr 2022
KRD vs VRD in high-risk multiple myeloma prior to autoHSCT
1:51
KRD vs VRD in high-risk multiple myeloma prior to autoHSCT
Mahmoud Gaballa • 22 Apr 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Mahmoud Gaballa • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Mahmoud Gaballa • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Mahmoud Gaballa • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Mahmoud Gaballa • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals